Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31048
Title: | Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy | Authors: | NIJST, Petra MARTENS, Pieter DAUW, Jeroen Tang, W. H. Wilson Voros, Gabor PENDERS, Joris BERTRAND, Philippe Willems, Rik BRUCKERS, Liesbeth VANDERVOORT, Pieter DUPONT, Matthias MULLENS, Wilfried |
Issue Date: | 2020 | Publisher: | ELSEVIER SCIENCE INC | Source: | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 75 (12) , p. 1426 -1438 | Abstract: | BACKGROUND The necessity of neurohumoral blockers in patients with heart failure who demonstrate normalized ejection fractions after cardiac resynchronization therapy remains unclear. OBJECTIVES The aim of this study was to investigate the feasibility and safety of neurohumoral blacker withdrawal in patients with normalized ejection fractions after cardiac resynchronization therapy. METHODS In this prospective, open-label, randomized controlled pilot trial with a 2 x 2 factorial design, subjects were randomized to withdrawal of renin-angiotensin-atdosterone system inhibitors and/or beta-btockers versus continuation of treatment. The primary endpoint was a recurrence of negative remodeling, defined as an increase in left ventricular end-systolic volume index of >15% at 24 months. The secondary endpoint was a composite safety endpoint of all-cause mortality, heart failure-related hospitalizations, and incidence of sustained ventricular arrhythmias at 24 months. RESULTS Eighty subjects were consecutively enrolled and randomized among 4 groups (continuation of neurohumorat blacker therapy, n = 20; withdrawal of renin-angiotensin-aldosterone system inhibitors, n = 20; withdrawal of betabtockers, n = 20; and withdrawal of renin-angiotensin-aldosterone system inhibitors and beta-blockers, n = 20). Of the 80 subjects, 6 (73%) met the primary and 4 (5%) the secondary endpoint. However, re-initiation of neurohumorat btockers occurred in 17 subjects because of hypertension or supraventricutar arrhythmias. CONCLUSIONS The incidence of the primary and secondary endpoints over a follow-up period of 2 years was tow in both the control group and in the groups in which neurohumorat btockers were discontinued. However, neurohumorat blacker withdrawal was hampered by cardiac comorbidities. | Notes: | Mullens, W (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. wilfried.mullens@zol.be |
Other: | Mullens, W (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. wilfried.mullens@zol.be | Keywords: | cardiac resynchronization therapy;heart failure with recovered ejection fraction;left bundle branch block;myocardial recovery;neurohumoral blockers | Document URI: | http://hdl.handle.net/1942/31048 | ISSN: | 0735-1097 | e-ISSN: | 1558-3597 | DOI: | 10.1016/j.jacc.2020.01.040 | ISI #: | WOS:000521282100007 | Rights: | © 2020 by the American College of Cardiology Foundation | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0735109720305118-main.pdf Restricted Access | Published version | 549.12 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
1
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
19
checked on Sep 12, 2024
Page view(s)
68
checked on Jul 20, 2022
Download(s)
10
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.